Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

NASDAQ:LXEO - US52886X1072 - Common Stock

4.78 USD
-0.07 (-1.44%)
Last: 8/28/2025, 3:01:09 PM
Fundamental Rating

2

Overall LXEO gets a fundamental rating of 2 out of 10. We evaluated LXEO against 547 industry peers in the Biotechnology industry. LXEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LXEO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LXEO had negative earnings in the past year.
LXEO had a negative operating cash flow in the past year.
In the past 5 years LXEO always reported negative net income.
In the past 5 years LXEO always reported negative operating cash flow.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LXEO's Return On Assets of -64.85% is in line compared to the rest of the industry. LXEO outperforms 41.86% of its industry peers.
LXEO has a Return On Equity (-82.60%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LXEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for LXEO has been increased compared to 1 year ago.
LXEO has a better debt/assets ratio than last year.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -0.12, we must say that LXEO is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.12, LXEO is doing good in the industry, outperforming 61.06% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that LXEO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, LXEO perfoms like the industry average, outperforming 46.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.12
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.43 indicates that LXEO has no problem at all paying its short term obligations.
LXEO has a Current ratio of 4.43. This is comparable to the rest of the industry: LXEO outperforms 49.54% of its industry peers.
A Quick Ratio of 4.43 indicates that LXEO has no problem at all paying its short term obligations.
The Quick ratio of LXEO (4.43) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.43
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.70% over the past year.
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LXEO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.31% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.86%
EPS Next 2Y16.27%
EPS Next 3Y10.41%
EPS Next 5Y14.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.27%
EPS Next 3Y10.41%

More info and screens

0

5. Dividend

5.1 Amount

LXEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (8/28/2025, 3:01:09 PM)

4.78

-0.07 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-13 2025-11-13/bmo
Inst Owners107.65%
Inst Owner Change47.89%
Ins Owners0.81%
Ins Owner Change-0.21%
Market Cap258.12M
Analysts87.14
Price Target17.78 (271.97%)
Short Float %10.69%
Short Ratio10.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.21%
Min EPS beat(2)-23.91%
Max EPS beat(2)13.49%
EPS beat(4)2
Avg EPS beat(4)-8.43%
Min EPS beat(4)-28.59%
Max EPS beat(4)13.49%
EPS beat(8)4
Avg EPS beat(8)-50.48%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.27%
PT rev (3m)-17.57%
EPS NQ rev (1m)5.5%
EPS NQ rev (3m)32.71%
EPS NY rev (1m)0.32%
EPS NY rev (3m)14.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)-3.26
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS0
BVpS2.56
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.43
Altman-Z -0.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
EPS Next Y12.86%
EPS Next 2Y16.27%
EPS Next 3Y10.41%
EPS Next 5Y14.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.8%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-57.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.53%
OCF growth 3YN/A
OCF growth 5YN/A